Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

The registrational trial is expected to support the Bavarian’s mpox/smallpox vaccine use in children between 2 and 11 years ...

The WHO declared mpox a global public health emergency for the second time in two years in August after a new variant of the ...

The World Health Organisation said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine September 24, 2024 Future of Healthcategory Bavarian says mpox vaccine approved by EU regulator for adolescents ...

An employee of the vaccine company Bavarian Nordic works in a laboratory of the company in Martinsried near Munich, Germany. Reuters The World Health Organization said on Monday it had approved ...

In September, after facing criticism on moving too slowly on vaccines, the World Health Organization cleared Bavarian Nordic's vaccine for mpox and said it was considering LC16, made by Japan's KM ...

COPENHAGEN, Denmark, October 29, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN ® mpox/smallpox vaccine in children 2 to 11 years of age.